Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00436527 · ClinicalTrials.gov registry record · Phase 4

Assess the Ability of MetroGel 1% to Deliver Moisture to Facial Skin After a Single Application

A Phase 4 study, sponsored by Galderma R&D.

Completed
Registry status
Phase 4
Development phase
26
Enrollment target

NCT00436527: Completed Phase 4 study, sponsored by Galderma R&D.

NCT00436527 is a Phase 4 study that has completed, run by Galderma R&D. The registered enrollment target is 26 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00436527, a Phase 4 study, has completed, sponsored by Galderma R&D.

COMPLETED
Registry status
Phase 4
Development phase
26 participants
Enrollment target

Study Summary

This eight-hour kinetic regression clinical study was conducted to assess the ability of MetroGel® 1% to deliver moisture to facial skin after a single application.

Interventions

  • DRUG Metronidazole gel 1%

Trial Details

FieldValue
Enrollment Target 26 participants
Start Date 2006-08
Est. Completion 2006-08
Phase Phase 4
Galderma R&D

158 total trials

What the finished NCT00436527 record still lists

NCT00436527 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 26 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (95% lower).

The record links to 0 conditions, and to 1 intervention - of which Metronidazole gel 1% is the first listed.

NCT00436527 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00436527 about?

NCT00436527 is a clinical study titled "Assess the Ability of MetroGel 1% to Deliver Moisture to Facial Skin After a Single Application". This eight-hour kinetic regression clinical study was conducted to assess the ability of MetroGel® 1% to deliver moisture to facial skin after a single application.

What is the current status of trial NCT00436527?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 26 participants. The study started on 2006-08. Estimated completion is 2006-08.

What interventions are being tested in trial NCT00436527?

The interventions under investigation include: Metronidazole gel 1% (DRUG).

Who is sponsoring clinical trial NCT00436527?

This trial is sponsored by Galderma R&D, which has 158 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00436527's enrollment target sits among peer trials

26 1655th of 2000 higher than 332 of 2,000 other Phase 4 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02646475 · 26 participants · Phase 1

    Metabolic Effects of Angiotensin-(1-7)

  • NCT03603223 · 26 participants · Phase 2

    Pembrolizumab in Treating Participants With Leukoplakia

  • NCT04063592 · 26 participants · NA

    AMI Construction in Lower Extremity Residual Limbs

  • NCT04906460 · 26 participants · Phase 1

    Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00436527, the US trial registry maintained by the National Library of Medicine. NCT00436527 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.